Valeant authorizes $100 million stock repurchase

The board of directors at Southern California's Valeant Pharmaceuticals International approved a $100 million repurchase of its outstanding common stock as part of its 2007 stock repurchase program. 

In a company press release, Valeant's chairperson and CEO J. Michael Pearson said, "The board's authorization of the additional $100 million to the share repurchase program underscores its continued confidence in our strategy and our commitment to enhancing shareholder value." The repurchase will bring the total authorized amount to $300 million. The board approved the first $200 million last June. 

- See Valeant's release
- get more at MSN

Suggested Articles

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.